Kimberly A. Gudzune
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kimberly A. Gudzune has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
Jeanne M. Clark
Division of General Internal Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA
18 shared publicationsSara N. Bleich
Department of Health Policy and Management Harvard T.H. Chan School of Public Health Boston Massachusetts USA
9 shared publications- Gerald J. Jerome
Towson University
7 shared publications Edmond P. Wickham
6 shared publications- Wendy L. Bennett
Department of Medicine, Division of General Internal Medicine, Johns Hopkins University School of Medicine
6 shared publications - Arlene Taylor Dalcin
Department of Medicine, Johns Hopkins University, Baltimore, MD, United States
5 shared publications
Latest Publications
- Open Access
- 8 June 2026
- Published by Elsevier in Obesity Pillars
- Vol. 19
Development of program requirements for obesity medicine fellowship training in the U.S.
- 8 June 2026
- Published by Elsevier in Obesity Pillars
- Vol. 19
Open AccessDevelopment of program requirements for obesity medicine fellowship training in the U.S.
- Open Access
- 8 January 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 161, 108219
The long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: Rationale, design, and baseline characteristics
- 8 January 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 161, 108219
Open AccessThe long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: Rationale, design, and baseline characteristics
- Open Access
- 30 October 2025
- Published by Elsevier in Obesity Pillars
- Vol. 16, 100223
An obesity care curriculum improves residents’ self-efficacy and clinical practice habits
- 30 October 2025
- Published by Elsevier in Obesity Pillars
- Vol. 16, 100223
Open AccessAn obesity care curriculum improves residents’ self-efficacy and clinical practice habits
- Open Access
Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial
Objective: This study aimed to apply The Lancet Diabetes & Endocrinology criteria for diagnosing obesity among clinical trial participants and understand participants' characteristics by obesity status. Methods: The criteria were operationalized and applied to baseline data from the Long‐term Effectiveness of the Anti‐obesity medication Phentermine (LEAP) trial (NCT05176626). Excess adiposity, organ and tissue dysfunction, and limitations to daily activities were assessed. We examined differences between participants with “no obesity,” “pre‐clinical obesity,” and “clinical obesity.” Results: Among the 860 participants, 0.8% had no obesity (mean BMI 29.0 kg/m 2 [SD 0.6]), 18.7% had pre‐clinical obesity (mean BMI 35.2 kg/m 2 [SD 3.5]), and 80.5% had clinical obesity (mean BMI 35.9 kg/m 2 [SD 4.3]). Participants with no/pre‐clinical obesity had lower mean SF‐12 mental component scores and greater baseline engagement with weight control strategies compared to those with clinical obesity. Participants with clinical obesity were older and, by definition, had a greater burden of cardiometabolic risk factors. Conclusions: Among clinical trial participants eligible for obesity pharmacotherapy, 19.5% were classified as having no/pre‐clinical obesity using the Lancet criteria. Applying the criteria was complicated in a well‐resourced trial setting, which suggests potential challenges in implementing these guidelines in real‐world practice.
Open AccessApplication of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial
Objective: This study aimed to apply The Lancet Diabetes & Endocrinology criteria for diagnosing obesity among clinical trial participants and understand participants' characteristics by obesity status. Methods: The criteria were operationalized and applied to baseline data from the Long‐term Effectiveness of the Anti‐obesity medication Phentermine (LEAP) trial (NCT05176626). Excess adiposity, organ and tissue dysfunction, and limitations to daily activities were assessed. We examined differences between participants with “no obesity,” “pre‐clinical obesity,” and “clinical obesity.” Results: Among the 860 participants, 0.8% had no obesity (mean BMI 29.0 kg/m 2 [SD 0.6]), 18.7% had pre‐clinical obesity (mean BMI 35.2 kg/m 2 [SD 3.5]), and 80.5% had clinical obesity (mean BMI 35.9 kg/m 2 [SD 4.3]). Participants with no/pre‐clinical obesity had lower mean SF‐12 mental component scores and greater baseline engagement with weight control strategies compared to those with clinical obesity. Participants with clinical obesity were older and, by definition, had a greater burden of cardiometabolic risk factors. Conclusions: Among clinical trial participants eligible for obesity pharmacotherapy, 19.5% were classified as having no/pre‐clinical obesity using the Lancet criteria. Applying the criteria was complicated in a well‐resourced trial setting, which suggests potential challenges in implementing these guidelines in real‐world practice.
An Update on the American Board of Obesity Medicine ( ABOM ): 2017–2024
Objective: This study aimed to describe the characteristics of American Board of Obesity Medicine (ABOM) physician diplomates over the last 8 years (2017–2024). Methods: Using the ABOM database, we conducted a cross‐sectional study of physicians who achieved initial ABOM certification between 2017 and 2024. Characteristics included demographics, primary medical specialty, years of obesity medicine experience, patient population, and practice setting. We conducted descriptive analyses and compared current characteristics with estimates extracted from the published ABOM 5‐year report (2012–2016). Results: Overall, 8640 physicians achieved initial ABOM certification between 2017 and 2024; 2068 achieved certification between 2012 and 2016. Between the 2012–2016 and 2017–2024 groups, notable differences were increases in physicians under age 40 years (22.7% vs. 47.6%, respectively), women (52.8% vs. 64.0%, respectively), and practicing obesity medicine for less than 2 years at initial certification (40.2% vs. 68.3%, respectively). The most common primary medical specialties were internal medicine (32.4%), family medicine (29.2%), and internal medicine subspecialties (14.2%). Conclusions: We found that recent ABOM diplomates are likely entering the field earlier in their careers and with fewer years of obesity medicine experience than the initial group. Future investigation is needed to understand how ABOM and other obesity organizations can best support these physicians in their transition to obesity medicine clinical practice.
An Update on the American Board of Obesity Medicine ( ABOM ): 2017–2024
Objective: This study aimed to describe the characteristics of American Board of Obesity Medicine (ABOM) physician diplomates over the last 8 years (2017–2024). Methods: Using the ABOM database, we conducted a cross‐sectional study of physicians who achieved initial ABOM certification between 2017 and 2024. Characteristics included demographics, primary medical specialty, years of obesity medicine experience, patient population, and practice setting. We conducted descriptive analyses and compared current characteristics with estimates extracted from the published ABOM 5‐year report (2012–2016). Results: Overall, 8640 physicians achieved initial ABOM certification between 2017 and 2024; 2068 achieved certification between 2012 and 2016. Between the 2012–2016 and 2017–2024 groups, notable differences were increases in physicians under age 40 years (22.7% vs. 47.6%, respectively), women (52.8% vs. 64.0%, respectively), and practicing obesity medicine for less than 2 years at initial certification (40.2% vs. 68.3%, respectively). The most common primary medical specialties were internal medicine (32.4%), family medicine (29.2%), and internal medicine subspecialties (14.2%). Conclusions: We found that recent ABOM diplomates are likely entering the field earlier in their careers and with fewer years of obesity medicine experience than the initial group. Future investigation is needed to understand how ABOM and other obesity organizations can best support these physicians in their transition to obesity medicine clinical practice.
- Open Access
- 27 August 2025
- Published by Elsevier in Obesity Pillars
- Vol. 16, 100204
Developing and implementing an obesity medicine fellowship program: Experience at a U.S. academic medical center
- 27 August 2025
- Published by Elsevier in Obesity Pillars
- Vol. 16, 100204
Open AccessDeveloping and implementing an obesity medicine fellowship program: Experience at a U.S. academic medical center
- Open Access
- 2 June 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 138, 109190
Reimagining primary care visits for people living with obesity: A Co-design and validation study
- 2 June 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 138, 109190
Open AccessReimagining primary care visits for people living with obesity: A Co-design and validation study
- 25 April 2025
- Published by Springer Nature
- p. 469-480
Emergence of a New Medical Subspecialty: The Case of Obesity Medicine
- 25 April 2025
- Published by Springer Nature
- p. 469-480
Emergence of a New Medical Subspecialty: The Case of Obesity Medicine
- Open Access
Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study
Objective: The objective of this study was to understand the perceptions of and drivers/barriers to antiobesity medication (AOM) use among people with obesity (PwO) and health care providers (HCPs) in the United States.Methods: In 2022, PwO and HCPs completed cross‐sectional surveys that included questions on perceptions of obesity management and AOMs. Data were analyzed using descriptive statistics.Results: Survey participants (1007 PwO and 474 HCPs) emphasized the effectiveness of lifestyle change and the patient's responsibility to address obesity. PwO reported a willingness to take newly approved AOMs long term. HCPs believed that their patients would adhere to AOMs long term if they experienced success. Both PwO and HCPs perceived an increased effectiveness of a multimodal approach to combining AOMs with HCP‐guided lifestyle intervention. Potential barriers to long‐term use of AOMs for both groups included concerns regarding long‐term side effects and outcomes, costs and insurance coverage, and perception of AOMs that do not align with treatment of a chronic disease.Conclusions: PwO and HCPs are interested in new AOM options, but educational gaps remain as a barrier to recommended multimodal chronic care. Ongoing education that includes the known effectiveness and safety data of newer AOMs and pending outcome trials could improve shared decision‐making in obesity care.
Open AccessPerceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study
Objective: The objective of this study was to understand the perceptions of and drivers/barriers to antiobesity medication (AOM) use among people with obesity (PwO) and health care providers (HCPs) in the United States.Methods: In 2022, PwO and HCPs completed cross‐sectional surveys that included questions on perceptions of obesity management and AOMs. Data were analyzed using descriptive statistics.Results: Survey participants (1007 PwO and 474 HCPs) emphasized the effectiveness of lifestyle change and the patient's responsibility to address obesity. PwO reported a willingness to take newly approved AOMs long term. HCPs believed that their patients would adhere to AOMs long term if they experienced success. Both PwO and HCPs perceived an increased effectiveness of a multimodal approach to combining AOMs with HCP‐guided lifestyle intervention. Potential barriers to long‐term use of AOMs for both groups included concerns regarding long‐term side effects and outcomes, costs and insurance coverage, and perception of AOMs that do not align with treatment of a chronic disease.Conclusions: PwO and HCPs are interested in new AOM options, but educational gaps remain as a barrier to recommended multimodal chronic care. Ongoing education that includes the known effectiveness and safety data of newer AOMs and pending outcome trials could improve shared decision‐making in obesity care.
- Open Access
- 12 February 2025
- Published by Wiley in Obesity Science & Practice
- Vol. 11 (1) , e70056
Centering Weight Management Clinical Decision Support in Primary Care on Patients With Obesity and Practitioners: A Proof‐Of‐Concept Study
Background: Clinical decision support systems (CDSS) are electronic health record tools that support practitioners' decision‐making at the point‐of‐care. CDSS may aid clinical care but are not often centered on patients or practitioners.Aims: To develop and preliminarily test a CDSS designed to support evidence‐based obesity treatment, promote a patient‐centered experience, and integrate with clinical workflows.Materials & Methods: The CDSS allowed patients to complete a pre‐visit questionnaire via the patient portal, which activated multiple elements for the primary care practitioner (PCP). A 3‐month proof‐of‐concept study was conducted among 10 PCPs at 5 clinics to determine usefulness, usability, and acceptability through validated surveys (mean score ≥ 2.5 signified positive outcome; max 5). Using t‐tests, pre‐post differences in PCPs' frequency of self‐reported clinical practices (1‐never; 5‐always) were examined.Results: Most PCPs were physicians with mean experience of 10.8 years (SD 7.5). Overall, mean scores for usefulness, usability, and acceptability were 3.2 (SD 0.8), 3.5 (SD 0.9), and 3.6 (SD 0.9), respectively. PCPs reported significant increases in three key clinical practices—counseling on behavioral interventions (3.1 vs. 3.9 [p < 0.01]), referring to weight‐loss programs (2.8 vs. 3.5 [p < 0.01]), and discussing anti‐obesity medications (3.3 vs. 3.8 [p = 0.02]).Conclusion: This weight management CDSS was useful and usable for PCPs and improved obesity‐related practice habits. Future studies need to evaluate its impact on patient outcomes.
- 12 February 2025
- Published by Wiley in Obesity Science & Practice
- Vol. 11 (1) , e70056
Open AccessCentering Weight Management Clinical Decision Support in Primary Care on Patients With Obesity and Practitioners: A Proof‐Of‐Concept Study
Background: Clinical decision support systems (CDSS) are electronic health record tools that support practitioners' decision‐making at the point‐of‐care. CDSS may aid clinical care but are not often centered on patients or practitioners.Aims: To develop and preliminarily test a CDSS designed to support evidence‐based obesity treatment, promote a patient‐centered experience, and integrate with clinical workflows.Materials & Methods: The CDSS allowed patients to complete a pre‐visit questionnaire via the patient portal, which activated multiple elements for the primary care practitioner (PCP). A 3‐month proof‐of‐concept study was conducted among 10 PCPs at 5 clinics to determine usefulness, usability, and acceptability through validated surveys (mean score ≥ 2.5 signified positive outcome; max 5). Using t‐tests, pre‐post differences in PCPs' frequency of self‐reported clinical practices (1‐never; 5‐always) were examined.Results: Most PCPs were physicians with mean experience of 10.8 years (SD 7.5). Overall, mean scores for usefulness, usability, and acceptability were 3.2 (SD 0.8), 3.5 (SD 0.9), and 3.6 (SD 0.9), respectively. PCPs reported significant increases in three key clinical practices—counseling on behavioral interventions (3.1 vs. 3.9 [p < 0.01]), referring to weight‐loss programs (2.8 vs. 3.5 [p < 0.01]), and discussing anti‐obesity medications (3.3 vs. 3.8 [p = 0.02]).Conclusion: This weight management CDSS was useful and usable for PCPs and improved obesity‐related practice habits. Future studies need to evaluate its impact on patient outcomes.